Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Daniel Longley has joined Almac Discovery on a part-time basis to assist in a three-year research project on deubiquitinating enzymes. Longley will continue to serve as deputy director at the Patrick Johnson Cancer Centre at Queen’s University Belfast.
Clinical-stage gene therapy company AVROBIO has appointed Diana Escolar to the role of chief medical officer. Escolar was the former chief medical officer at miRagen Therapeutics.
Bristol Myers Squibb
Bristol Myers Squibb’s chief commercial officer Chris Boerner has added oversight of the company’s hematology program, replacing former executive vice president and hematology head Nadim Ahmed.
Eric Mosbrooker, former chief commercial officer at Audentes, has been named chief operating officer for Cognoa.
Jim Caggiano, former CEO of Dendreon Pharmaceuticals, has been named CEO of Evolve Biologics.
Christopher Moxham has been promoted to chief scientific officer at Fulcrum Therapeutics. Previously, Moxham served as Fulcrum’s senior vice president of discovery research.
MeMed has named Troy Boutelle vice president of commercial, North America and general manager of the U.S. Boutelle was formerly the vice president of sales and marketing at Eurofins-Viracor.
MindMed has added Robert Barrow to the company’s staff as the new chief development officer. Barrow was most recently the director of drug development and discovery at the Usona Institute.
Mirum has named Alexey Kutahov the general manager of Europe, Middle East and Africa regions. Most recently, Kutahov was the general manager of Europe at Sarepta.
José Vega has been named chief safety officer for Moderna. Prior to this appointment, Vega was chief safety officer at Merck.
Robert Knight has been appointed to the role of chief medical officer at NexImmune. Prior to this appointment, Knight was vice president at Kite Pharmaceuticals.
NextCure has appointed Han Myint to the role of chief medical officer. Myint was previously the chief medical officer at NexImmune.
Novavax has named Henrietta Ukwu the company’s chief regulatory and quality officer. Ukwu was most recently chief regulatory officer and global head of quality and regulatory at Otsuka Pharmaceuticals.
Oncology Newco, a newly formed oncology business entity from bluebird bio, has named Nick Leschly CEO of the company.
Clare Grace has been appointed chief patient officer at Parexel. Formerly, Grace was the vice president of site and patient access at Syneos Health Clinical Solutions.
Receptor Life Sciences
Former chief operating officer of Engage Therapeutics, Mark Theeuwes, has been named CEO of Receptor Life Sciences.
Thomas Soloway has taken the helm of T-knife as its newest CEO. Formerly, Soloway served as chief operating officer of Audentes Therapeutics.
Tiziana Life Sciences
Tiziana Life Sciences has tapped Neil Graham to take on the role of chief medical officer. Graham comes from Regeneron, where he served as vice president of immunology and inflammation.
Frederic Fasano has been named president and chief operating officer of Valeo Pharma. Fasano is also CEO of the company and will continue to serve in this capacity.
Perry Celentano has been named interim chief operating officer of Valneva. Celentano formerly held leadership roles at Merck, Novartis and Dynavax.
Viridian Therapeutics, formerly miRagen Therapeutics, has named Jonathan Violin CEO of the company. Violin most recently served as CEO of both Quellis Biosciences and Dianthus Therapeutics. Viridian has also named Barrett Katz the company’s new chief medical officer. Katz was formerly the chief medical officer at BridgeBio Pharma.
Ian Mortimer has taken over Xenon Pharmaceuticals as its new president and CEO. Mortimer was formerly the company’s chief financial officer.